Drugs / NY-ESO-l 157-165 (165V)
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01008527 Background | Oct 2009 → Sep 2013 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-l 157-165 (165V) | “NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients” NCT01008527 ↗ |
| Modality | Peptide | “NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides” NCT01008527 ↗ |
| Route | Subcutaneous | “Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections” NCT01008527 ↗ |